Treatment of prostate cancer with SBRT is an area of significant controversy for many in the radiation oncology community despite radiobiologic data that strongly suggest the prostate would be an excellent SBRT target. Recently, new data have emerged that show promising outcomes with minimal toxicity for CyberKnife SBRT of prostate cancer. In the following we present the motivating factors for prostate cancer SBRT followed by a critical evaluation of the current literature and discussion of the future of prostate cancer treatment with SBRT.
References
1.
GagnonG. J.NasrN. M.LiaoJ. J.MolzahnI.MarshD.McRaeD.HendersonF. C.Sr.Treatment of spinal tumors using cyberknife fractionated stereotactic radiosurgery: Pain and quality-of-life assessment after treatment in 200 patients. Neurosurgery64, 297–306; discussion 306–297 (2009).
2.
RusthovenK. E.KavanaghB. D.CardenesH.StieberV. W.BurriS. H.FeigenbergS. J.ChidelM. A.PughT. J.FranklinW.KaneM.GasparL. E.SchefterT. E.Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol27, 1572–1578 (2009).
3.
SvedmanC.KarlssonK.RutkowskaE.SandstromP.BlomgrenH.LaxI.WersallP.Stereotactic body radiotherapy of primary and metastatic renal lesions for patients with only one functioning kidney. Acta Oncol47, 1578–1583 (2008).
4.
TimmermanR.PaulusR.GalvinJ.MichalskiJ.StraubeW.BradleyJ.FakirisA.BezjakA.VideticG.JohnstoneD.FowlerJ.GoreE.ChoyH.Stereotactic body radiation therapy for inoperable early stage lung cancer. Jama303, 1070–1076.
5.
MartinA.GayaA.Stereotactic body radiotherapy: A review. Clin Oncol (R Coll Radiol)22, 157–172.
BuyyounouskiM. K.PriceR. A.Jr.HarrisE. E.MillerR.TomeW.SchefterT.ParsaiE. I.KonskiA. A.WallnerP. E.Stereotactic body radiotherapy for primary management of early-stage, low- to intermediate-risk prostate cancer: Report of the American Society for Therapeutic Radiology and Oncology Emerging Technology Committee. Int J Radiat Oncol Biol Phys76, 1297–1304.
8.
KingC. R.BrooksJ. D.GillH.PawlickiT.CotrutzC.PrestiJ. C.Jr.Stereotactic Body Radiotherapy for Localized Prostate Cancer: Interim Results of a Prospective Phase II Clinical Trial. Int J Radiat Oncol Biol Phys73, 1043–1048 (2009).
9.
FriedlandJ. L.FreemanD. E.Masterson-McGaryM. E.SpellbergD. M.Stereotactic body radiotherapy: An emerging treatment approach for localized prostate cancer. Technol Cancer Res Treat8, 387–392 (2009).
10.
KatzA. J.SantoroM.AshleyR.DiblasioF.WittenM.Stereotactic body radiotherapy for organ-confined prostate cancer. BMC Urol10, 1 (2010).
11.
TownsendN. C.HuthB. J.DingW.GarberB.MoorevilleM.ArrigoS.LamondJ.BradyL. W.Acute Toxicity After CyberKnife-Delivered Hypofractionated Radiotherapy for Treatment of Prostate Cancer. Am J Clin Oncol (In Press).
12.
FullerD. B.NaitohJ.ReillyM.LeeC.Virtual HDR Prostate CyberKnife Radiosurgery: Efficacy, Toxicity and Quality of Life In: 2009 CyberKnife Users' Meeting. Hollywood, FL (2009).
13.
EadeT. N.HanlonA. L.HorwitzE. M.BuyyounouskiM. K.HanksG. E.PollackA.What dose of external-beam radiation is high enough for prostate cancer?Int J Radiat Oncol Biol Phys68, 682–689 (2007).
14.
KupelianP. A.ThakkarV. V.KhuntiaD.ReddyC. A.KleinE. A.MahadevanA.Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Long-term outcomes. Int J Radiat Oncol Biol Phys63, 1463–1468 (2005).
15.
ZelefskyM. J.ChanH.HuntM.YamadaY.ShippyA. M.AmolsH.Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol176, 1415–1419 (2006).
16.
FowlerJ. F.RitterM. A.ChappellR. J.BrennerD. J.What hypofractionated protocols should be tested for prostate cancer?Int J Radiat Oncol Biol Phys56, 1093–1104 (2003).
17.
BrennerD. J.MartinezA. A.EdmundsonG. K.MitchellC.ThamesH. D.ArmourE. P.Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys52, 6–13 (2002).
18.
FowlerJ. F.The radiobiology of prostate cancer including new aspects of fractionated radiotherapy. Acta Oncol44, 265–276 (2005).
19.
BrennerFractionationD. J. and late rectal toxicity. Int J Radiat Oncol Biol Phys60, 1013–1015 (2004).
20.
CollinsC. D.Lloyd-DaviesR. W.SwanA. V.Radical external beam radiotherapy for localised carcinoma of the prostate using a hypofractionation technique. Clin Oncol (R Coll Radiol)3, 127–132 (1991).
21.
CahlonO.ZelefskyM. J.ShippyA.ChanH.FuksZ.YamadaY.HuntM.GreensteinS.AmolsH.Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: Toxicity and biochemical outcomes. Int J Radiat Oncol Biol Phys71, 330–337 (2008).
22.
MartinezA. A.DemanesJ.VargasC.SchourL.GhilezanM.GustafsonG. S.High-Dose-Rate Prostate Brachytherapy: An Excellent Accelerated-Hypofractionated Treatment for Favorable Prostate Cancer. Am J Clin Oncol (2009).
23.
DemanesD. J.RodriguezR. R.SchourL.BrandtD.AltieriG.High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results. Int J Radiat Oncol Biol Phys61, 1306–1316 (2005).
24.
MadsenB. L.HisR. A.PhamH. T.FowlerJ. F.EsaguiL.CormanJ.Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: First clinical trial results. Int J Radiat Oncol Biol Phys67, 1099–1105 (2007).
25.
RomanelliP.SchaalD.W.AdlerJ. R.Image-guided radiosurgical ablation of intra- and extra-cranial lesions. Technol Cancer Res Treat5, 421–428 (2006).
26.
KingC. R.LehmannJ.AdlerJ. R.HaiJ.CyberKnife radiotherapy for localized prostate cancer: Rationale and technical feasibility. Technol Cancer Res Treat2, 25–29 (2003).
27.
HossainS.XiaP.HuangK.DescovichM.ChuangC.GottschalkA. R.RoachM.IIIMaL.Dose Gradient Near Target-Normal Structure Interface for Nonisocentric CyberKnife and Isocentric Intensity-Modulated Body Radiotherapy for Prostate Cancer. Int J Radiat Oncol Biol Phys (In Press).
28.
HossainS.XiaP.ChuangC.VerheyL.GottschalkA. R.MuG.MaL.Simulated real time image guided intrafraction tracking-delivery for hypofractionated prostate IMRT. Med Phys35, 4041–4048 (2008).
29.
XieY.DjajaputraD.KingC. R.HossainS.MaL.XingL.Intrafractional motion of the prostate during hypofractionated radiotherapy. Int J Radiat Oncol Biol Phys72, 236–246 (2008).
30.
ChoiC.ChoG.KimK.ParkM.JoC.LeeS.YooM.KimK.YangH.Stereotactic Radiation Therapy of Localized Prostate Cancer Using CyberKnife. Int J Radiat Oncol Biol Phys69, S375 (2007).
31.
FreemanD. E.FriedlandJ. L.Masterson-McGaryM. E.Stereotactic Radiosurgery for Low-Intermediate Risk Prostate Cancer: An Emerging Treatment Approach. Am J Clin Oncol33, 208 (2010).
32.
SandaM. G.DunnR. L.MichalskiJ.SandlerH. M.NorthouseL.HembroffL.LinX.GreenfieldT. K.LitwinM. S.SaigalC. S.MahadevanA.KleinE.KibelA.PistersL. L.KubanD.KaplanI.WoodD.CiezkiJ.ShahN.WeiJ. T.Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med358, 1250–1261 (2008).
33.
KatzA.SantoroM.CyberKnife radiosurgery for early carcinoma of the prostate: A three year experience. Int J Radiat Oncol Biol Phys75, S312–S313 (2009).
34.
FullerD. B.NaitohJ.LeeC.HardyS.JinH.Virtual HDR CyberKnife treatment for localized prostatic carcinoma: Dosimetry comparison with HDR brachytherapy and preliminary clinical observations. Int J Radiat Oncol Biol Phys70, 1588–1597 (2008).
35.
MeierR.CotrutzC.MRI-planned Stereotactic Body Radiotherapy for Organ-confined Prostate Cancer: Feasibility and Early ResultsInt J Radiat Oncol Biol Phys75, S334 (2009).
36.
WiegnerE. A.KingC. R.Sexual Function after Stereotactic Body Radiotherapy for Prostate Cancer: Results of a Prospective Clinical Trial. Int J Radiat Oncol Biol Phys (In Press).
37.
MartinezA. A.GustafsonG.GonzalezJ.ArmourE.MitchellC.EdmundsonG.SpencerW.StrombergJ.HuangR.ViciniF.Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer. Int J Radiat Oncol Biol Phys53, 316–327 (2002).
38.
KatzA.SantoroM.AshleyR.DiblasioF.WittenM.Stereotactic Body Radiotherapy as Boost for Organ-Confined Prostate Cancer. Technol Cancer Res Treat (In Press).
FowlerJ. F.The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol62, 679–694 (1989).
42.
KingC. R.LoA.KappD. S.Testicular dose from prostate cyberknife: A cautionary note. Int J Radiat Oncol Biol Phys73, 636–637; author reply 637 (2009).
43.
FullerD. B.Testicular dose from prostate cyberknife: A cautionary note in regard to King et al., Int J Radiat Oncol Biol Phys73, 637 (2009).
44.
YogeswarenS.TheB.MaiW.ChildressC.McGaryJ.GrantW.ButlerE.Radiation dose to testicles and serum testosterone levels in low risk prostate cancer patients undergoing intensity-modulated radiation therapy (IMRT)Int J Radiat Oncol Biol Phys60, S456 (2004).
45.
SannazzariG. L.RagonaR.ReddaM. G. RuoGiglioliF. R.IsolatoG.GuarneriA.CT-MRI image fusion for delineation of volumes in three-dimensional conformal radiation therapy in the treatment of localized prostate cancer. Br J Radiol75, 603–607 (2002).
46.
MartinezA. A.DemanesD. J.GalalaemR.VargasC.BertermannH.RodriguezR.GustafsonG.AltieriG.GonzalezJ.Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime. Int J Radiat Oncol Biol Phys62, 1322–1331 (2005).
47.
RoachM.IIIDeSilvioM.ValicentiR.GrignonD.AsbellS. O.LawtonC.ThomasC. R.Jr.ShipleyW. U.Whole-pelvis, “mini-pelvis,” or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial. Int J Radiat Oncol Biol Phys66, 647–653 (2006).
48.
PommierP.ChabaudS.LagrangeJ. L.RichaudP.LesaunierF.Le PriseE.WagnerJ. P.HayM. H.BeckendorfV.SuchaudJ. P.du ChatelardP. M. PabotBernierV.VoirinN.PerolD.CarrieC.Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. J Clin Oncol25, 5366–5373 (2007).
49.
ZelefskyM. J.ShiW.YamadaY.KollmeierM. A.CoxB.ParkJ.SeshanV. E.Postradiotherapy 2-year prostate-specific antigen nadir as a predictor of long-term prostate cancer mortality. Int J Radiat Oncol Biol Phys75, 1350–1356 (2009).
50.
PollackA.ZagarsG. K.External beam radiotherapy dose response of prostate cancer. Int J Radiat Oncol Biol Phys39, 1011–1018 (1997).
51.
ZelefskyM. J.LeibelS. A.GaudinP. B.KutcherG. J.FleshnerN. E.VenkatramenE. S.ReuterV. E.FairW. R.LingC. C.FuksZ.Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys41, 491–500 (1998).
52.
HanksG. E.HanlonA. L.PinoverW. H.HorwitzE. M.PriceR. A.SchultheissT.Dose selection for prostate cancer patients based on dose comparison and dose response studies. Int J Radiat Oncol Biol Phys46, 823–832 (2000).
